Global Infectious Diseases Rapid Diagnostic Testing Market Report (2020-2025)
The global infectious diseases rapid diagnostic testing market is segmented by product (assays and platforms), by technology (respiratory infection, gastro-intestinal infectious, nervous systems, hospital acquired, and others), by disease (bacterial disease, viral infections), by end user, and by region. COVID-19 impact analysis with pre COVID-19 and post COVID-19 market values analysis is included in the report.
.svg)
Market Snapshot
Market Overview
In the recent times, the global outbreak of COVID-19 has resulted in an increased demand for rapid diagnostic testing. This causes a growth in the rapid diagnostic testing market. The increase in incidence of pandemics is likely to cause a rapid increase in rapid diagnostic assays, decentralised laboratories and more budget for R&D activities. The level of strain on the healthcare system is rising due to the growing infection rates. The focus of the governments on bolstering the healthcare systems is causing a need for better diagnostic testing systems.
The market for infectious rapid diagnostic testing is used for identifying various infectious diseases within a restricted clinical environment. The success of the testing depends on quickly identifying the target analyte within a set time frame. These diagnostic tests play a critical role in navigating through pandemics such as Ebola virus disease (EVD), SARS-CoV, MERS and COVID-19.
Segmentation by Product
It is estimated that the RT-PCR market will grow from $687.31 million in 2019 to $1621.5 million by 2025. The INAAT technology is expected to grow from $167.3 million in 2019 to $383.5 million in 2025. The Lateral Flow Immunoassay market is expected to grow from $242.9 million to $570.1 million in 2025. The Enzyme Immunoassay market is expected to grow from $105.6 million to $204.6 million in 2025. The other technologies form the remaining share of the market. Some of the key products offered under RT-PCR include ARIES GBS Assay, Accula Flu A/Flu B, Aptima HBV Quant assay, Solana Respiratory Viral Panel and ID NOW COVID-19.
The most recent infections caused across the world have been caused by viruses such as COVID-19, SARS, MERS, Ebola and Zika virus. Bacterial infections such as pneumonia, tuberculosis and malaria also contribute to the increasing disease burden while the remaining infections are caused by other markets. Some of the prominent diseases in this field include Influenza, Viral Infections, Hepatitis, Tuberculosis and Hospital Acquired Infections.
Segmentation by Geography
The most promising countries in terms of the growth of the market include the U.S., Italy, China, India, Brazil and Kingdom of Saudi Arabia. The factors which make U.S. a favourable market for the market include strong legacy and high impact of COVID-19. The rapidly evolving diagnostic landscape and immense growth opportunities make India a promising prospect. The highly effective healthcare system in Italy make the country ideal for the growth of the process.
Competitive Landscape
Major Players
Table of Contents
1. Research Methodology and Scope
2. Executive Summary
3. Impact of COVID-19 on Infectious Diseases Rapid Testing Market
3.1 Market Value Estimation Pre-COVID19 vs Post COVID-19
3.2 Impact of COVID-19 on Market in Different Countries
4. Market Dynamics
4.1 Drivers
4.2 Restraints
5. Competitive Landscape
5.1 Key Strategies Adopted by Major Companies
5.2 Company Share Analysis
6. Rapid Testing Market Segmentation by Product
6.1 Assays
6.2 Platforms
7. Rapid Testing Market Segmentation by Technology
7.1 Real Time PCR
7.2 Isothermal Nuclear Acid Amplification Technology (INAAT)
7.3 Lateral Flow Immunoassays
7.4 Enzyme Immunoassays
7.5 Others
8. Rapid Testing Market Segmentation by Application
8.1 Respiratory Infection
8.2 Gastro-Intestinal Infection
8.3 Nervous System Infection
8.4 Hospital Acquired Infection
8.5 Sexually Transmitted Infections
8.5 Others
9. Rapid Testing Market Segmentation by Disease
9.1 Bacterial Disease
9.1.1 Hospital Acquired Infections
9.1.2 Tuberculosis
9.1.3 CT/NG
9.1.4 Others
9.2 Viral Infections
9.2.1 Influenza Virus
9.2.2 Hepatitis
9.2.3 HIV/AIDS
9.2.4 HPV
9.2.4 Others
9.3 Other Infections
10. Rapid Testing Market Segmentation by End User
10.1 Hospitals
10.2 Clinics
10.3 Diagnostic Centres
10.4 Other End Users
11. Rapid Diagnostic Testing Market by Region
11.1 North America
11.1.1 United States
11.1.2 Canada
11.1.3 Mexico
11.2 Europe
11.2.1 United Kingdom
11.2.2 Spain
11.2.3 Italy
11.2.4 Germany
11.2.5 Russia
11.2.6 Rest of Europe
11.3 Asia-Pacific
11.3.1 China
11.3.2 India
11.3.3 Japan
11.3.4 Australia
11.3.5 South Korea
11.3.6 Rest of Asia-Pacific
11.4 South America
11.4.1 Brazil
11.4.2 Rest of South America
11.5 Middle East and Africa
12. Company Profiles
12.1 Abbott Laboratories
12.2 Roche
12.3 Danaher Corporation
12.4 Luminex Corporation
12.5 BGI Group
12.6 Hologic Inc
12.7 Thermo Fisher Scientific
12.8 Becton Dickinson and Company
12.9 bioMerieux
12.10 Bio-Rad Laboratories
13. Appendix
Research Methodology
